News About: Pharm. Industry
Jeil's TS-1 may shake whole cancer drug markets.
Jeil Pharmaceutical Co. will introduce an attractive ant-cancer drug named TS-1 formulated with 3 components such as Tegaflu, Kimeracil and Oteracil under the technical licence with Japanese Taiho who originally devel...
Domestic drug-related patent applications plunged 47% in 2002
Recent statistics showed that Korea's drug-related patents applications in 2002 toped 404 cases, down 448 cases compared with 852 cases from a year earlier, meaning that the domestic pharmaceutical business en...
Boryung to implement ethical management.
Chairman Kim Seung-ho of Boryung announced "The Ethical Management Guideline for the company executives and staffs" on Jan. 29 so that all company members should keep their ethical decision making and action in their ...
Tightened tax rules hit domestic pharmaceutical firms
Beginning in 2004, the National Tax Service says companies that spend 500,000 won or more entertaining their customers, clients or employees must prove that the meetings are business-related, while people on the recei...
7 companies fined on charge of hospital bid rigging.
In earlier government's public bidding for the purchase of vaccines, 7 drug companies were accused of a bid rigging and fined thereof.
Fair Trade Commission (FTC) inspected the public bidding process for the purcha...
Speedy listing of Iressa's insurance price urged
In a recent meeting with the local Health World Network over the pending health insurance price of Iressa, an anticancer agent, AstraZeneca Korea said that the government is still in the process of assessing its reimb...
Abbott Korea launches obesity-free company campaign
Abbott Korea, a pharmaceutical maker of Reductil (sibutramine hydrochloride monohydrate) intended for the management of obesity, said recently its ongoing obesity-free company campaign is gaining positive response fro...
Earlier introduction of generic drug becomes critical to survive.
To keep the prescription drug markets and to survive from harsh competitive environments, an earlier introduction of generic drugs than other rivals will be one of the most critical strategy for the domestic drug corp...
Yuhan achieved 7.5% sales growth with 8.3% net profits in 2003.
The 2003 Yuhan annual management report revealed 305.5 billion won of the sales (7.5% over the previous year), 45.7 billion won of gross profits (2.0% growth), 76.3 billion won of ordinary income (9.8%) and 49.5 billi...
Brand marketing essential in modern marketplace
With the prevailing understanding that brand image is a means of controlling not only an organization but also influencing the minds of customers, it is often argued that domestic pharmaceutical firms should reflect t...
